Percutaneous sclerotherapy of lymphangiomas.

Abstract

Percutaneous sclerotherapy with doxycycline is safe and appears effective for palliative treatment of unresectable lymphangiomas on the basis of our initial clinical experience.

Neutropenia in Sirolimus Treated Patients of Lymphatic Malformation: A Case Series

“…For this reason, recurrence rates tend to range between 50-100% [11]. Percutaneous sclerotherapy using doxycycline was first reported [12]. Commonly used variants include bleomycin and OK432 [13].…”

Uso de OK-432 em crianças com linfangioma

“…Depending on the size of these cysts, they are classified as macrocystic (cystic hygroma), microcystic (cavernous and capillary) and intermediary, in which cases both forms are presented. [1][2][3][4][5][6] The natural history of a lymphangioma is characterized by progressive growth, compression and infiltration of adjacent structures, resulting in an overall clinical picture which depends on location. Spontaneous remission can occur although it is rare.…”

“…1 The pathophysiology of these lesions is not fully established, having been classified as hamartomas, lymphatic malformations or benign tumors. 1,2,[4][5][6] Lymphangioma treatment depends on size and clinical presentation, location and the risk of complications. The most widely accepted therapy is surgery that attempts to preserve the nervous and vascular structures involved, which is, however, not always possible.…”

“…[1][2][3][4][5][6][7][8] The limitations of surgical solutions have awoken interest in other therapeutic methods, such as the administration of sclerosing agents such as bleomycin and hypotonic salt solutions that provoke an inflammation of the vascular endothelium leading to total or partial remission of the lymphangioma. [1][2][3][4][5][6]8 These substances can be diffused, via the walls of the cyst, to adjacent tissues, which can provoke an inflammatory reaction and scar retraction, which may extend beyond the limits of the original lymphangioma, with unsatisfactory aesthetic results and increased difficulties for future surgery. 4 Despite the limitations that make sclerosing agents unsatisfactory for the treatment of lymphangioma, a new agent, OK-432, produced by lyophilization of a culture of low virulence Su strains of group A Streptococcus pyogenes treated with penicillin G potassium, has been used with good results.…”

“…[1][2][3][4][5][6]8 These substances can be diffused, via the walls of the cyst, to adjacent tissues, which can provoke an inflammatory reaction and scar retraction, which may extend beyond the limits of the original lymphangioma, with unsatisfactory aesthetic results and increased difficulties for future surgery. 4 Despite the limitations that make sclerosing agents unsatisfactory for the treatment of lymphangioma, a new agent, OK-432, produced by lyophilization of a culture of low virulence Su strains of group A Streptococcus pyogenes treated with penicillin G potassium, has been used with good results. [1][2][3][5][6][7][8][9][10] It has been approved for use by the Japanese Health Ministry for use as a biological response modifier and was initially used in clinical trials for neoplasms of the head and neck.…”